Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study 0 07.05.2020 16:18 BusinessInsider.com.au Moderna stock surged as much as 16% early Thursday after the company announced its coronavirus vaccine candidate received FDA approval for phase 2 trials. More » Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
